• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Nevro Corp.

    11/14/24 5:31:36 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care
    Get the next $NVRO alert in real time by email
    SC 13D/A 1 sc13da209455055_11142024.htm AMENDMENT NO. 2 TO THE SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 2)1

    Nevro Corp.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    64157F103

    (CUSIP Number)

    GLENN W. WELLING

    ENGAGED CAPITAL, LLC

    610 Newport Center Drive, Suite 950

    Newport Beach, California 92660

    (949) 734-7900

     

    RYAN NEBEL

    OLSHAN FROME WOLOSKY LLP

    1325 Avenue of the Americas

    New York, New York 10019

    (212) 451-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    November 12, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 64157F103

      1   NAME OF REPORTING PERSON  
             
            Engaged Capital Flagship Master Fund, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CAYMAN ISLANDS  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         565,452  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              565,452  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            565,452  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            1.5%  
      14   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 64157F103

      1   NAME OF REPORTING PERSON  
             
            Engaged Capital, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         565,452  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              565,452  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            565,452  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            1.5%  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 64157F103

     

      1   NAME OF REPORTING PERSON  
             
            Engaged Capital Holdings, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         565,452  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              565,452  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            565,452  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            1.5%  
      14   TYPE OF REPORTING PERSON  
             
            OO  

      

    4

    CUSIP No. 64157F103

     

      1   NAME OF REPORTING PERSON  
             
            Glenn W. Welling  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            OO  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         565,452  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        10   SHARED DISPOSITIVE POWER  
               
              565,452  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            565,452  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            1.5%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    5

    CUSIP No. 64157F103

    The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned (“Amendment No. 2”). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein.

    Item 3.Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended and restated to read as follows:

    The Shares purchased by Engaged Capital Flagship Master were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 565,452 Shares beneficially owned by Engaged Capital Flagship Master is approximately $5,411,168, including brokerage commissions.

    Item 5.Interest in Securities of the Issuer.

    Items 5(a), (c) and (e) are hereby amended and restated to read as follows:

    (a)       The aggregate percentage of Shares reported owned by each person named herein is based upon 37,471,622 Shares outstanding as of November 6, 2024, which is the total number of Shares outstanding as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024.

    As of the date hereof, Engaged Capital Flagship Master directly beneficially owned 565,452 Shares, constituting approximately 1.5% of the Shares outstanding.

    Engaged Capital, as the general partner and investment adviser of Engaged Capital Flagship Master, may be deemed to beneficially own the 565,452 Shares owned by Engaged Capital Flagship Master, constituting approximately 1.5% of the Shares outstanding. Engaged Holdings, as the managing member of Engaged Capital, may be deemed to beneficially own the 565,452 Shares owned by Engaged Capital Flagship Master, constituting approximately 1.5% of the Shares outstanding. Mr. Welling, as the Founder and CIO of Engaged Capital and sole member of Engaged Holdings, may be deemed to beneficially own the 565,452 Shares owned by Engaged Capital Flagship Master, constituting approximately 1.5% of the Shares outstanding.

    The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

    (c)       Schedule A annexed hereto lists all transactions in securities of the Issuer by the Reporting Persons during the past 60 days. All of such transactions were effected in the open market unless otherwise noted therein.

    (e)       As of November 12, 2024, the Reporting Persons ceased to beneficially own more than 5% of the outstanding Shares.

    6

    CUSIP No. 64157F103

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024

      Engaged Capital Flagship Master Fund, LP
       
      By: Engaged Capital, LLC
    General Partner
       
      By:

    /s/ Glenn W. Welling

        Name: Glenn W. Welling
        Title: Founder and Chief Investment Officer

     

     

      Engaged Capital, LLC
       
      By:

    /s/ Glenn W. Welling

        Name: Glenn W. Welling
        Title: Founder and Chief Investment Officer

     

     

      Engaged Capital Holdings, LLC
       
      By:

    /s/ Glenn W. Welling

        Name: Glenn W. Welling
        Title: Sole Member

     

     

     

    /s/ Glenn W. Welling

      Glenn W. Welling

     

     

    7

    CUSIP No. 64157F103

    SCHEDULE A

    Transactions in Securities of the Issuer During the Past 60 Days

    Nature of the Transaction

    Securities

    Purchased/(Sold)

    Price Per

    Security($)

    Date of

    Purchase/Sale

     

    ENGAGED CAPITAL FLAGSHIP MASTER FUND, LP

     

    Sale of Common Stock (75,104) 5.3678 11/04/2024
    Sale of Common Stock (4,931) 5.3397 11/04/2024
    Sale of Common Stock (103,635) 5.5575 11/05/2024
    Sale of Common Stock (7,596) 5.5951 11/05/2024
    Sale of Common Stock (2,822) 5.5914 11/05/2024
    Sale of Common Stock (130,200) 5.7842 11/06/2024
    Sale of Common Stock (20,098) 5.8972 11/06/2024
    Sale of Common Stock (15,221) 5.8403 11/06/2024
    Sale of Common Stock (16,361) 5.4654 11/07/2024
    Sale of Common Stock (41,588) 5.6399 11/07/2024
    Sale of Common Stock (132,444) 5.1437 11/08/2024
    Sale of Common Stock (301,325) 5.3839 11/12/2024
    Sale of Common Stock (5,132) 5.7007 11/12/2024
    Sale of Common Stock (168,219) 6.1274 11/12/2024
    Sale of Common Stock (16,500) 5.9500 11/12/2024
    Sale of Common Stock (1,191) 4.8659 11/13/2024
    Sale of Common Stock (389,610) 4.5867 11/13/2024
    Sale of Common Stock (55,700) 4.1516 11/14/2024
    Sale of Common Stock (389,827) 4.1792 11/14/2024

     

    Get the next $NVRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVRO

    DatePrice TargetRatingAnalyst
    2/10/2025$4.50 → $5.85Underperform → Hold
    Jefferies
    2/7/2025$6.00 → $5.85Neutral → Overweight
    Piper Sandler
    12/3/2024$5.00Equal Weight
    Wells Fargo
    12/2/2024$9.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    8/9/2024Sell → Neutral
    Citigroup
    8/8/2024Underperform → Peer Perform
    Wolfe Research
    8/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024Neutral → Underweight
    JP Morgan
    More analyst ratings

    $NVRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:33 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Director Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:35 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Director Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:38 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nevro Corp.

      SC 13G - NEVRO CORP (0001444380) (Subject)

      12/4/24 4:27:18 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Nevro Corp.

      SC 13D/A - NEVRO CORP (0001444380) (Subject)

      11/14/24 5:31:36 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nevro Corp.

      SC 13G/A - NEVRO CORP (0001444380) (Subject)

      11/14/24 5:18:25 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

      AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

      2/6/25 9:30:21 AM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

      REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induceme

      1/21/25 4:30:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Financials

    Live finance-specific insights

    See more
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

      AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

      2/6/25 9:30:21 AM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Reports Third-Quarter 2024 Financial Results

      Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma

      11/11/24 4:05:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Nevro Enters Into Cooperation Agreement With Engaged Capital

      Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi

      2/21/24 4:06:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Appoints Jon R. Shear as Vice President, Corporate Development

      REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately.   "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and

      4/19/21 7:00:00 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications

      REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately.   "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a

      11/30/20 7:00:00 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Nevro Corp.

      15-12G - NEVRO CORP (0001444380) (Filer)

      4/14/25 8:30:09 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Nevro Corp.

      EFFECT - NEVRO CORP (0001444380) (Filer)

      4/8/25 12:15:06 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.

      SCHEDULE 13D/A - NEVRO CORP (0001444380) (Subject)

      4/4/25 3:49:25 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Nevro upgraded by Jefferies with a new price target

      Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously

      2/10/25 7:02:54 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Nevro from Neutral to Overweight and set a new price target of $5.85 from $6.00 previously

      2/7/25 8:27:53 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Nevro with a new price target

      Wells Fargo initiated coverage of Nevro with a rating of Equal Weight and set a new price target of $5.00

      12/3/24 7:38:11 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care